Anti-human papillomavirus therapeutics: facts & future

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Human Papillomavirus (HPV) is the primary cause of cervical cancer, yet effective treatments remain elusive.
• Conventional therapies focus on ablating HPV-induced lesions but do not eliminate the virus.
• Recent advancements aim to target HPV infection directly, moving beyond prophylactic measures.

Purpose of the Study:

• To provide an overview of current conventional therapies for HPV-associated diseases.
• To discuss the potential of non-ablative anti-HPV treatment modalities.
• To explore strategies for eliminating early-stage HPV or suppressing viral oncogenes.

Main Methods:

• Review of conventional physical ablation techniques (cryotherapy, LEEP, laser, radiotherapy).
• Exploration of therapeutic vaccines and immunomodulators (interferons, imiquimod).
• Assessment of antiviral approaches including RNA interference (RNAi), nucleotide analogs, antioxidants, and herbal derivatives.

Main Results:

• Conventional therapies offer partial treatment for localized HPV lesions.
• Therapeutic vaccines, immunomodulators, and various antiviral strategies show promise in pre-clinical and clinical studies.
• Non-ablative methods could eliminate early HPV or control oncogene expression.

Conclusions:

• There is a critical need for effective treatments to combat HPV infection and associated cancers.
• Emerging non-ablative therapies offer potential for early-stage HPV elimination or oncogene suppression.
• Continued research into novel therapeutic strategies is essential for managing HPV infection.